EVOLUS, INC. Long-Term Debt, Maturity, Remainder of Fiscal Year
EVOLUS, INC. (EOLS) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $0 as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2026-08-05
- 2026-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2026-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2023-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2023-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-04 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-02 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-08 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-02 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-10 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-10 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |